Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM. Kanakkanthara A, et al. Among authors: zanfagnin v. Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. Epub 2021 Nov 22. Cancer Res. 2022. PMID: 34810199 Free PMC article.
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, Jatoi A, Block MS, Langstraat CL, Glaser GE, Dinh TA, Robertson MW, Camoriano JK, Butler KA, Copland JA, Weroha SJ. Colon-Otero G, et al. Among authors: zanfagnin v. ESMO Open. 2020 Oct;5(5):e000926. doi: 10.1136/esmoopen-2020-000926. ESMO Open. 2020. PMID: 33109627 Free PMC article. Clinical Trial.
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.
Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell GL, Conrads T, Sood AK, Orr D, Holmes LM, Gevaert M, Crosswell HE, DesRochers TM. Shuford S, et al. Among authors: zanfagnin v. Sci Rep. 2019 Aug 1;9(1):11153. doi: 10.1038/s41598-019-47578-7. Sci Rep. 2019. PMID: 31371750 Free PMC article.
Sentinel Lymph Nodes and Precision Surgery in Gynecologic Cancer.
Ghoniem K, Shazly SA, Dinoi G, Zanfagnin V, Glaser GE, Mariani A. Ghoniem K, et al. Among authors: zanfagnin v. Clin Obstet Gynecol. 2020 Mar;63(1):12-23. doi: 10.1097/GRF.0000000000000517. Clin Obstet Gynecol. 2020. PMID: 31855904 Review.
The role of surgery in recurrent endometrial cancer.
Zanfagnin V, Ferrero A, Biglia N, Aletti G, Gill SE, Makdisi PB, Multinu F, Mariani A. Zanfagnin V, et al. Expert Rev Anticancer Ther. 2016 Jul;16(7):741-50. doi: 10.1080/14737140.2016.1190650. Epub 2016 Jun 13. Expert Rev Anticancer Ther. 2016. PMID: 27269480 Free article. Review.
23 results